

M Christina Cox

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6509935/m-christina-cox-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125
papers

2,838
citations

28
h-index

50
g-index

125
ext. papers

3,191
ext. citations

3.5
avg, IF

4.06
L-index

#	Paper	IF	Citations
125	Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worlds. <i>Cancer Letters</i> , 2022 , 524, 144-150	9.9	0
124	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1214-1222	2.2	21
123	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021 , 35, 787-795	10.7	19
122	Exercise training (ET) in adult and elderly patients receiving anti-lymphoma treatments is feasible and may improve the provision of care. <i>Leukemia and Lymphoma</i> , 2021 , 62, 560-570	1.9	1
121	Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. <i>In Vivo</i> , 2020 , 34, 1407-1413	2.3	
120	Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma Not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the Literature. <i>Diagnostics</i> , 2020 , 10,	3.8	3
119	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020 , 38, 439-445	1.3	3
118	Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 913-925	7.4	4
117	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020 , 29, e13174	2.4	1
116	All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 841-846	3.5	1
115	The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1958-1964	1.9	2
114	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFN γ Dendritic Cells and Rituximab: a Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 5231-5241	12.9	18
113	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. <i>Investigational New Drugs</i> , 2019 , 37, 548-558	4.3	4
112	Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e321-e323	2	
111	Relapsing Long-Lasting Garcin Syndrome Revealing Skull Base Diffuse B Cell Lymphoma: The Diagnosis through the "Hartel β Route". <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019 , 80, 105-108	1.5	1
110	The neutrophil/lymphocyte ratio ≥ 5 is a prognostic marker in diffuse large B-cell lymphoma: a retrospective analysis from the database of the Italian regional network Rete Ematologica del Lazio per i Linfomi (RELLI). <i>Leukemia and Lymphoma</i> , 2019 , 60, 3386-3394	1.9	7
109	Lenalidomide improves the therapeutic effect of an interferon- γ dendritic cell-based lymphoma vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 1791-1804	7.4	10

108	Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2019 , 134, 2880-2880	2.2	1
107	Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019 , 24, 1246-1252	5.7	7
106	Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab. <i>British Journal of Haematology</i> , 2019 , 184, 223-231	4.5	4
105	Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. <i>British Journal of Haematology</i> , 2019 , 185, 940-944	4.5	30
104	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study). <i>Oncologist</i> , 2018 , 23, 1033-1038	5.7	3
103	Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018 , 180, 600-602	4.5	1
102	The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 182, 741-742	4.5	3
101	DEVEC metronomic schedule for aggressive B and T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7563-7563	2.2	
100	Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit. <i>British Journal of Haematology</i> , 2018 , 183, 819-822	4.5	5
99	The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 226-229	1.9	4
98	Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. <i>Hematological Oncology</i> , 2017 , 35, 69-78	1.3	19
97	Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. <i>PLoS ONE</i> , 2017 , 12, e0181097	3.7	51
96	Improving Provision of Care for Long-term Survivors of Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, e1-e9	2	8
95	TCD4 lymphocytosis in rheumatoid and psoriatic arthritis patients following TNF α blocking agents. <i>Journal of Translational Medicine</i> , 2017 , 15, 38	8.5	2
94	Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. <i>Hematological Oncology</i> , 2017 , 35, 561-566	1.3	30
93	Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1295-1306	7.4	5
92	Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. <i>Journal of Leukocyte Biology</i> , 2016 , 99, 87-96	6.5	48
91	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2370-4	1.9	4

90	Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1823-30	1.9	23
89	Personalized Immunotherapy in Follicular Lymphoma By Intranodal IFN-Dendritic-Cell Combined to Anti-CD20 Antibody. <i>Blood</i> , 2016 , 128, 2976-2976	2.2	
88	The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 3049-3049	2.2	1
87	The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry. <i>Blood</i> , 2016 , 128, 3050-3050	2.2	
86	NK Cell Activation in the Antitumor Response Induced by IFN- γ -Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients. <i>Journal of Immunology</i> , 2016 , 197, 795-806	5.3	18
85	The immunoglobulin isotype matters in diffuse-large-B-cell lymphoma with serum paraproteinaemia. <i>Annals of Hematology</i> , 2015 , 94, 681-2	3	1
84	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 756-64	6.4	33
83	Breast Implant-Associated Anaplastic Large Cell Lymphoma: Proposal for a Monitoring Protocol. <i>Plastic and Reconstructive Surgery</i> , 2015 , 136, 144e-151e	2.7	33
82	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. <i>Oncotarget</i> , 2015 , 4, e990773	7.2	20
81	Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1671-6	1.9	17
80	Phenotypically and Functionally Altered T Cell Compartment in DLBCL Patients at Diagnosis and Its Long-Term Modification upon Chemoimmunotherapy Regimen. <i>Blood</i> , 2015 , 126, 1529-1529	2.2	2
79	Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice, the Lenamant Study. <i>Blood</i> , 2015 , 126, 3946-3946	2.2	3
78	Metronomic Chemotherapy Is Effective and Well Tolerated in Relapsed/Refractory Elderly Patients with Aggressive B- and T-Cell Lymphomas. <i>Blood</i> , 2015 , 126, 5080-5080	2.2	
77	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. <i>Blood</i> , 2015 , 126, 3862-3862	2.2	
76	Neutrophil to Lymphocyte Ratio at Diagnosis Is an Independent Prognostic Factor in Diffuse Large B-Cell Lymphoma: Results of a Large Multicenter Study Involving 931 Patients. <i>Blood</i> , 2015 , 126, 1465-1465	2.3	23
75	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014 , 99, 125-30	6.6	64
74	Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. <i>PLoS ONE</i> , 2014 , 9, e93903	3.7	23
73	Perception of hepatitis B virus infection reactivation-related issues among specialists managing hematologic malignancies: result of an Italian survey. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2564-71	1.9	9

72	Cutaneous manifestations of systemic non-Hodgkin lymphomas (NHL): study and review of literature. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 133-41	4.6	7
71	Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies. <i>Molecular Oncology</i> , 2014 , 8, 221-31	7.9	24
70	Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2014 , 124, 3074-3074	2.2	1
69	Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8530-8530	2.2	
68	Prognostic Role of Serum Albumin Level in DLBCL before and during the Rituximab Era. Retrospective GISL Study over 738 Cases. <i>Blood</i> , 2014 , 124, 5411-5411	2.2	
67	Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Treated with Chemo-Immunotherapy. <i>Blood</i> , 2014 , 124, 3027-3027	2.2	
66	Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 160, 207-15	4.5	51
65	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 13-33	3.5	74
64	Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2974-6	2.2	11
63	Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment. <i>European Journal of Haematology</i> , 2013 , 91, 183-6	3.8	5
62	Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?. <i>Radiation Oncology</i> , 2012 , 7, 129	4.2	13
61	Anti-Helicobacter Pylori Therapy in Primary MALT Lymphoma of Rectum. <i>Tumori</i> , 2012 , 98, e105-e110	1.7	4
60	Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012 , 53, 263-9 ^{1.9}	1.9	21
59	Eosinophilic Dermatitis Associated with Haematological Malignancies: A Report of Two Cases. <i>European Journal of Inflammation</i> , 2012 , 10, 247-250	0.3	1
58	Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset.. <i>Blood</i> , 2012 , 120, 2659-2659	2.2	1
57	Lenalidomide Is Effective in Heavily Pretreated Non Hodgkin Lymphoma (NHL): Analysis of a Retrospective Data Collection. <i>Blood</i> , 2012 , 120, 3694-3694	2.2	2
56	Anti-Helicobacter pylori therapy in primary MALT lymphoma of rectum. <i>Tumori</i> , 2012 , 98, e105-10	1.7	5
55	Patients with hematological malignancies and serological signs of prior resolved hepatitis B. <i>World Journal of Gastrointestinal Oncology</i> , 2012 , 4, 37-45	3.4	7

54	HCV infection, B-cell non-Hodgkin B lymphoma and immunochemotherapy: Evidence and open questions. <i>World Journal of Gastrointestinal Oncology</i> , 2012 , 4, 46-53	3.4	6
53	Les liaisons dangereuses P Hepatitis C, Rituximab and B-cell non-Hodgkin B lymphomas. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2012 , 3, 21-8	3	2
52	Distinct Phenotypic and Functional Immunological Alterations Characterize the Peripheral Blood Compartment of Patients with Diffuse Large B Cell Lymphoma (DLBCL).. <i>Blood</i> , 2012 , 120, 2653-2653	2.2	
51	HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin B lymphoma treated with rituximab-containing regimens. <i>Digestive and Liver Disease</i> , 2011 , 43, 139-42	3.3	30
50	CD4(+)/CD56(+) hematodermic neoplasm. <i>European Journal of Dermatology</i> , 2011 , 21, 291-2	0.8	
49	Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?. <i>American Journal of Hematology</i> , 2011 , 86, 957	7.1	12
48	Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin B lymphoma: a case report. <i>Scandinavian Journal of Infectious Diseases</i> , 2011 , 43, 750-2		4
47	Specific effects exerted by B-lymphoproliferative diseases on peripheral T-lymphocyte protein expression. <i>British Journal of Haematology</i> , 2010 , 150, 463-72	4.5	3
46	Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. <i>Annals of Oncology</i> , 2010 , 21, 1486-1491	10.3	72
45	Primary cutaneous Hodgkin lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, e52-3	4.5	14
44	Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 2692-2692	2.2	
43	Erythema annulare centrifugum associated with mantle b-cell non-Hodgkin B lymphoma. <i>Acta Dermato-Venereologica</i> , 2009 , 89, 319-20	2.2	11
42	Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?. <i>Annals of Hematology</i> , 2009 , 88, 283-4	3	2
41	Prognostic tools in follicular lymphomas. <i>Expert Review of Hematology</i> , 2009 , 2, 549-62	2.8	10
40	Radioimmunotherapy of heavily pre-treated, non-Hodgkin B lymphoma patients: efficacy and safety in a routine setting. <i>Anticancer Research</i> , 2009 , 29, 4771-7	2.3	5
39	Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008 , 141, 265-8	4.5	53
38	Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1745-51	1.9	84
37	Efficacy of Yttrium-90 Zevalin Outside of Clinical Trials: Preliminary Results of a Retrospective Bi-Center Study. <i>Blood</i> , 2008 , 112, 5015-5015	2.2	

36	Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. <i>Leukemia</i> , 2007 , 21, 340-50	10.7	470
35	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. <i>Annals of Oncology</i> , 2007 , 18, 346-50	10.3	95
34	Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. <i>Journal of Neuro-Oncology</i> , 2007 , 81, 197-9	4.8	38
33	Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. <i>Oncologist</i> , 2006 , 11, 285-91	5.7	51
32	The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. <i>Leukemia</i> , 2006 , 20, 1783-9	10.7	96
31	HCV Infection in Nongastric Marginal Zone B-Cell Lymphoma of MALT.. <i>Blood</i> , 2005 , 106, 987-987	2.2	
30	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 298-306	1.9	45
29	Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. <i>The Hematology Journal</i> , 2004 , 5, 24-31		4
28	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. <i>British Journal of Haematology</i> , 2004 , 125, 203-12	4.5	22
27	Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. <i>American Journal of Clinical Pathology</i> , 2004 , 122, 298-306	1.9	24
26	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2004 , 89, 1468-75	6.6	17
25	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003 , 101, 2125-31	2.2	280
24	P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003 , 121, 730-8	4.5	24
23	Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/MLL+ translocation in leukaemia. <i>British Journal of Haematology</i> , 2003 , 121, 953-5	4.5	7
22	Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. <i>The Hematology Journal</i> , 2003 , 4, 263-70		19
21	Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002 , 11, 349-57		17
20	Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. <i>Transfusion and Apheresis Science</i> , 2002 , 26, 103-10	2.4	7
19	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients. <i>Leukemia</i> , 2001 , 15, 903-9	10.7	57

18	New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. <i>Leukemia Research</i> , 2001 , 25, 349-51	2.7	12
17	A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0). <i>Cancer Genetics and Cytogenetics</i> , 2000 , 118, 76-9		2
16	A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes. <i>Annals of Hematology</i> , 2000 , 79, 138-42	3	19
15	P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. <i>Leukemia Research</i> , 1999 , 23, 451-65	2.7	30
14	Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. <i>Leukemia</i> , 1998 , 12, 1056-63	10.7	71
13	A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias. <i>American Journal of Clinical Pathology</i> , 1998 , 109, 24-31	1.9	33
12	Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 1998 , 92, 695-697	2.2	9
11	P-glycoprotein expression in de novo acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 1997 , 27, 257-74.9		26
10	Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes. <i>Blood</i> , 1997 , 89, 621-629	2.2	73
9	A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. <i>Leukemia Research</i> , 1997 , 21, 575-80	2.7	12
8	Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis. <i>Annals of Hematology</i> , 1996 , 72, 208-15	3	26
7	FISH analysis for CML monitoring?. <i>Annals of Hematology</i> , 1996 , 73, 113-9	3	30
6	Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia. <i>Annals of Hematology</i> , 1995 , 71, 13-27	3	8
5	Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (M0). <i>Cancer Genetics and Cytogenetics</i> , 1995 , 80, 66-7		8
4	Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy. <i>Cancer Genetics and Cytogenetics</i> , 1995 , 84, 15-8		20
3	CD7 expression in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 1995 , 17, 111-9	1.9	37
2	Minimally differentiated acute myeloid leukaemia (AML-M0): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. <i>British Journal of Haematology</i> , 1994 , 88, 784-93	4.5	42
1	All-trans retinoic acid plus low doses of cytarabine for the treatment of "poor-risk" acute myeloid leukemias. <i>Annals of Hematology</i> , 1993 , 66, 59-60	3	6

